TB1301的急性毒性实验研究  

Experimental Study on Acute Toxicity of TB1301

作　　者：孙继朋 

机构地区：[1]山东众山生物科技有限公司,山东日照276807

出　　处：《山东化工》2014年第2期106-107,109,共3页Shandong Chemical Industry

摘　　要：TB1301是抗慢性粒细胞白血病（CML）的新实体化合物,属四氢化萘酰胺类化合物,是伊马替尼的me-better药物.目的：观察灌胃给药和静脉注射TB1301对昆明小鼠的急性毒性.方法：用半数之死量法（LD50）观察TB1301灌胃给药和静脉注射对昆明小鼠的急性毒性,观察其一般情况.结论：TB1301灌胃给药的LD50为766.61 mg/kg,95％的可信限为537.25～ 949.49 mg/kg;TB1301静脉给药的LD50为118.20 mg/kg,95％的可信限为94.42 ～ 140.08 mg/kg.TB1301 as a new chemical entity of the anti -chronic myeloid leukemia（ CML）, is a kind of imatinib me -better drugs. Objective： Experimental study on acute toxicity of TB1301 in Kunming mice. Methods： The acute toxicity of TB1301 was studied in Kunming mice with lethal dose 50% method （ LD50 ）. General status were measured to evaluate the toxicity. Conclusion： TB1301 LD50 （ i. g） was 766.61 mg/kg with its 95 % confidence interval of 537.25 - 949.49 mg,/kg. TB1301 LD50 （ i. v） was 118.20 mg/kg with its 95% confidence interval of 94.42 - 140.08 mg/kg.

关 键 词：TB1301 急性毒性实验 昆明小鼠 LD50 

分 类 号：R965[医药卫生—药理学]